AIC-100 is under clinical development by AffyImmune Therapeutics and currently in Phase I for Anaplastic Thyroid Cancer. According to GlobalData, Phase I drugs for Anaplastic Thyroid Cancer have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AIC-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AIC-100 overview
AIC-100 is under development for the treatment of solid tumors (in combination with PD-1/cytokines), anaplastic thyroid cancer, differentiated thyroid cancer, follicular thyroid cancer, papillary thyroid cancer, medullary thyroid cancer, gastric cancer, non-small cell lung cancer (NSCLC) and cervical cancer (CC). The therapeutic candidate constitutes chimeric antigen receptor T cells (CAR-T). It targets cells expressing intercellular adhesion molecule-1 (ICAM-1).
It was also under development for the treatment of triple negative breast cancer (TNBC).
AffyImmune Therapeutics overview
AffyImmune Therapeutics is a clinical-stage biopharmaceutical company that develops novel, first-in-class, affinity-tuned CAR T cell therapies. The company’s lead product, AIC100, is an ICAM-1-directed (intercellular adhesion molecule 1) CAR T therapy being developed for patients with advanced thyroid cancer. AffyImmune Therapeutics’s proprietary technology utilizes ICAM-1/LFA-1 interaction (lymphocyte function-associated antigen 1), which potentially addresses critical CAR T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion. The company also developing a pipeline of therapeutics for oncologic indications. AffyImmune Therapeutics is headquartered in Natick, Massachusetts, the US.
For a complete picture of AIC-100’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
